Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketotifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.97 |
| ▸ | DRD3 | P35462 | 7/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.97 |
| ▸ | DRD1 | P21728 | 5/20 | 0.97 |
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.97 |
| ▸ | HTR2A | P28223 | 4/20 | 0.97 |
| ▸ | HTR2C | P28335 | 4/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.97 |
| ▸ | HTR3A | P46098 | 3/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.97 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.97 |
| ▸ | HTR6 | P50406 | 3/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketotifen SCHEMBL223510 | 0.99 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL29356083 | 0.99 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL4436 | 0.99 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL3386047 | 0.97 | DRD3 (0.97) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1171289 | 0.97 | DRD3 (0.97) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL28259803 | 0.96 | DRD3 (0.95) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1171294 | 0.94 | DRD3 (0.91) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL9060252 | 0.93 | DRD3 (0.89) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL5968240 | 0.92 | DRD3 (0.87) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL28259804 | 0.91 | DRD3 (0.98) | DRD3HRH1CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030031718-A1 | Ophthalmic compositions and use | WONG MICHELLE (US) | 2003-02-13 | — | — | US | claimed |
| US-20010049369-A1 | Brimonidine compositions and methods for retinal degeneration | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE | 2001-12-06 | — | — | US | claimed |
| CN-117836005-A | Composition for pharmaceutical tablet, pharmaceutical tablet using the same, and method for producing the same | 三菱化学株式会社 | 2024-04-05 | — | — | CN | disclosed |
| CN-111646982-B | Synthesis method of norketotifen | 浙江凯普化工有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-111646982-A | Synthesis method of norketotifen | 浙江凯普化工有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-1922059-B1 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS | NOVARTIS AG (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-20130165480-A1 | Stabilized and Preserved Ketotifen Ophthalmic Compositions | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
| US-20130102634-A1 | Stabilized and Preserved Ketotifen Ophthalmic Compositions | NOVARTIS AG | 2013-04-25 | — | — | US | disclosed |
| US-20120157496-A1 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS | TSAO FU-PAO (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095050-A1 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS | TSAO FU-PAO (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2343048-A2 | Stabilized and preserved ketotifen ophthalmic compositions | Novartis AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| EP-1926472-A2 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS | Novartis AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1922059-A2 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS | Novartis AG (CH) | 2008-05-21 | — | — | EP | disclosed |
| US-20070048388-A1 | Stabilized and preserved ketotifen ophthalmic compositions | TSAO FU-PAO | 2007-03-01 | — | — | US | disclosed |
| WO-2007025094-A2 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007025092-A2 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| US-20070048389-A1 | Stabilized and preserved ketotifen ophthalmic compositions | TSAO FU-PAO | 2007-03-01 | — | — | US | disclosed |
| EP-0788792-B1 | MATRIX TYPE PATCH PREPARATION | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-5866157-A | MIXTURE OF ADHESIVE, ACTIVE MATERIALS, ORGANIC ACID, HYDROPHOBIC HIGH MOLECULAR MATERIAL, TACCKIFIER RESIN, PLASTICIZER AND ABSORPTION PROMOTER | HISAMITSU PHARMACEUTICAL CO., LTD. (JP) | 1999-02-02 | — | — | US | disclosed |
| EP-0788792-A1 | MATRIX TYPE PATCH PREPARATION | Hisamitsu Pharmaceutical Co., Inc. (JP) | 1997-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049369-A1 | Brimonidine compositions and methods for retinal degeneration | NR2E3, MTNR1A, MTNR1B | HRH1 1342/4885DRD3 218/4885CHRM2 24/4885 |
| US-20030031718-A1 | Ophthalmic compositions and use | CMA1, CPA3, CHIA | HRH1 19/4885DRD3 2462/4885CHRM2 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.